These are the stocks posting the largest moves before the bell.Market Insiderread more
A Ministry of Commerce spokesperson did not mention any U.S. actions specifically, but it's been a tense couple of weeks for the trade negotiations.World Politicsread more
U.S. stock index futures were sharply lower Thursday as U.S.-China trade worries persisted with more companies suspending business with Chinese telecom giant Huawei.US Marketsread more
Tesla was set for its seventh straight day of losses after more analysts joined the growing list of those concerned with its finances.Investingread more
British Prime Minister Theresa May could announce her resignation in the next few days, according to U.K. media reports, as she faces increasing pressure from members of her...Europe Politicsread more
With Tesla shares skidding, two experts weigh in on what could be next for the automaker and its volatile stock.Trading Nationread more
A federal judge in New York City on Wednesday said Deutsche Bank and Capital One can turn over financial documents related to President Donald Trump and his businesses in...Politicsread more
Strategist Robert Buckland says global stocks have gained 7% on an annualized rate since 2010, which how much dividends have gone up in that time.Marketsread more
Analysts at Barclays "can't believe it's not meat," projecting huge growth for the nascent alternative food industry over 10 years.Investingread more
Makan Delrahim still has not made up his mind and appears to remain open to the potential $26.5 billion merger of T-Mobile and Sprint.Technologyread more
Chinese government-aligned experts are stressing that the U.S. will need to negotiate a trade agreement with Asia's largest economy.China Economyread more
The U.S. Food and Drug Administration just released its guidance on a category of software called "clinical decision support," which is designed to help doctors make more data-driven decisions about patient care.
It sounds wonky, but companies for years have been begging for clarity on whether this type of software is regulated -- or it isn't.
Experts say that lack of clarity is holding back start-ups and big companies alike in their attempt to bring new technologies to health. That includes Apple's plans to use its smartwatch to detect irregularities with the heart's rhythm and notify users if they need a medical consultation.
"I know developers who sat in my office and told me they didn't build a life-saving feature because they didn't know if it would be regulated or not," said Morgan Reed, president of an app developers' interest group called ACT.
Three documents from the FDA remove some doubts by describing various types of medical software and what sorts of claims would be regulated.
Reed said it's now clear that if a doctor makes the decision and diagnosis, and uses software to make more informed decisions about treatment, that software would not be regulated.
It would be regulated, however, if the software makes a diagnosis. For instance, if it notifies a user that they have a specific medical condition.
Reed said this category of software is so important as it takes some of the guesswork out of medicine.
Previously, doctors made decisions based on patients they've seen with a similar condition and background. "If you're lucky, that's 500 people who look like you," said Reed. But with new technology from "thousands of doctors on millions of patients," he said, treatments will be more evidence-based.
Apple, Google, Fitbit and others are all working with FDA as it figures out how to fast-track the approval process for digital health companies.
Some people in the industry think the guidance does not go far enough.
Some clinical decision support software is more "risky" to a patient than others. For instance, some app makers will recommend chemotherapy to a cancer patient based on information in their database. Others will merely use data to predict a risk score for populations of people who are more likely to develop migraines.
Bradley Merrill Thompson, an FDA expert and lawyer with the firm Epstein, Becker & Green, would have liked to see FDA distinguish between these various use-cases based on risk.
"We didn't get that," he wrote in an email. "Worse, it appears based on the guidance that the FDA is not interested in drawing that line."